Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
- 31 December 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Clinical Lipidology
- Vol. 5 (6), 483-492
- https://doi.org/10.1016/j.jacl.2011.09.001
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Hypertriglyceridemia and Its Pharmacologic Treatment Among US AdultsArchives of Internal Medicine, 2009
- Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemiaJournal of Clinical Lipidology, 2009
- Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin TreatmentCirculation, 2008
- Triglycerides and the Risk of Coronary Heart DiseaseCirculation, 2007
- Non–High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart DiseaseThe American Journal of Cardiology, 2006
- Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With DyslipidemiaDiabetes, 2002
- Hypertriglyceridemia: new insights and new approaches to pharmacologic therapyThe American Journal of Cardiology, 2001
- An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemiaHeart, 2001
- Effects of Simvastatin and omega‐3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemiaJournal of Internal Medicine, 1998
- n-3 fatty acids and serum lipoproteins: human studiesThe American Journal of Clinical Nutrition, 1997